Allarity Therapeutics (ALLR)
Develops stenoparib with DRP®-guided patient selection for advanced recurrent ovarian cancer.
$1.06
vs last close−0.05 (−4.50%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Insiders | 8.22% | 1.31M shares | |
|---|---|---|---|
| 6 holders · as of May 14, 2026 | |||
| Other | 91.78% | 14.60M shares | |
| remainder | |||
15.91M company shares as of Sep 23, 2026 · holders as of their latest filing
13F
No 13F holders on record.
13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Form 4
Latest trades
No open-market trades in the last 12 months.
House and Senate disclosures
Not reported.